Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
REHOVOT, Israel, March 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced today that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing. The tests have demonstrated the efficacy of Lavie Bio's biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide. Building on these positive outcomes, the companies are progressing to a second year of validation trials in field experiments.
以色列雷霍沃特，2024 年 3 月 19 日 /PRNewswire/-- Lavie Bio 有限公司. 是一家开发基于微生物组、计算驱动的生物刺激剂和生物农药新产品的领先农业生物制剂公司，也是Evogene Ltd.（纳斯达克股票代码：EVGN）（TASE：EVGN）（TASE：EVGN）的子公司，今天宣布，它将延长其生物杀菌剂的联合验证试验 拜耳股份公司，在成功进行第一年的实验室和温室测试之后，成为农业行业的全球领导者。这些测试证明了Lavie Bio的生物杀菌剂在解决影响全球水果和蔬菜的毁灭性疾病方面的功效。在这些积极结果的基础上，两家公司正进入第二年的实地实验验证试验。